Cardiff Oncology
CRDF
58 hedge funds and large institutions have $10.7M invested in Cardiff Oncology in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
0% more funds holding
Funds holding: 58 → 58 (0)
1.13% less ownership
Funds ownership: 18.29% → 17.16% (-1.1%)
18% less capital inflows, than outflows
Capital inflows: $730K | Capital outflows: $886K
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
93% less call options, than puts
Call options by funds: $5K | Put options by funds: $75K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
+$336K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$141K |
| 3 |
Renaissance Technologies
New York
|
+$98.8K |
| 4 |
Two Sigma Investments
New York
|
+$33.4K |
| 5 |
Callan Capital
La Jolla,
California
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$279K |
| 2 |
Morgan Stanley
New York
|
-$137K |
| 3 |
Millennium Management
New York
|
-$84.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$60.5K |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
-$55K |
CRDF Hedge Fund Activity: Q4 2022 in Review
58 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2022, worth a combined $10.7M — down 12% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CRDF positions and 10 closed out — a net gain of 2 holders — while 9 added to existing stakes and 13 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $336K. The largest seller was Citadel Advisors, cutting an estimated $279K.
- 58 institutional investors held Cardiff Oncology (CRDF) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $10.7M of Cardiff Oncology stock for Q4 2022, down 12% quarter-over-quarter.
- 12 funds opened new Cardiff Oncology positions in Q4 2022 and 10 closed out, a net change of +2 holders.
- The largest Cardiff Oncology buyer in Q4 2022 was GSA Capital Partners, an estimated $336K added.
- The largest Cardiff Oncology seller in Q4 2022 was Citadel Advisors, an estimated $279K sold.
Based on aggregated 13F filings for Q4 2022.